China NMPA grants IND clearance for trial of Ascletis’ Covid-19 drug

ASC11 was found to have potent antiviral activity against BA.1 and BA.5 Omicron variants.

Neurocrine therapy fails to meet endpoint in epileptic encephalopathy trial

The trial evaluated NBI-827104 when given once a day up to 13 weeks in paediatric EE-CSWS patients.

Tetra Bio-Pharma reports results from trial of ARDS-003 and Favipiravir

Onternabez plays a key role in mitigating the inflammatory response in various inflammatory condition targets.

Alzheimer’s disease drug development: three major questions for 2023

After a chaotic 2022 that saw both drug development successes and failures, the Alzheimer’s disease field faces questions over upcoming data and new therapeutic approaches.